The Effect Of Pentoxifylline On Blood Biomarkers In Patients With Cerebral Infarction Combined With Senile Debilitating Syndrome: Implications For Prognosis

Cerebral infarction combined with senile debilitating syndrome seriously affects the quality of life of patients, this study analyzed the effect of pentoxifylline on the expression of blood biomarkers in patients with this disease and its relationship with prognosis. 100 patients with cerebral infarction combined with senile debilitating syndrome admitted to our hospital from December 2022 to December 2024 were divided into control and study groups, both groups were treated with basic therapy, and study group were additionally treated with pentoxifylline. The neurological deficit degree (NIHSS score) and Montreal Cognitive Assessment (MoCA) score, coagulation function indicators, blood rheology indicators, inflammatory indicators, clinical efficacy and adverse reactions were analyzed. The relationship of blood biomarker expression with prognosis was assessed using logistic regression analysis and receiver operating characteristic (ROC) curve. After treatment, all indicators in both groups were superior to the pre-treatment (P<0.05). NIHSS score, haematological indicators, inflammatory indicators and adverse reaction incidences of study group were below to control group, MoCA score, coagulation function indexes and clinical efficacy were above to control group (P<0.05). Logistic regression and ROC results showed the effect of blood biomarker expression and prognosis were remarkably correlated. The treatment is efficacious and worthy of clinical promotion.